Market Overview - The three major indices in the Shanghai and Shenzhen markets showed mixed performance, with total trading volume decreasing to 1.56 trillion yuan [1][7] - The ADP employment report for November indicated a decrease of 32,000 jobs, marking the largest decline in two and a half years, which was significantly below the expected increase of 10,000 jobs [2][8] - The probability of the Federal Reserve cutting interest rates by 25 basis points in December is close to 90%, as indicated by CME's FedWatch tool, further reinforcing market expectations for a dovish stance [2][8] Policy Developments - The State-owned Assets Supervision and Administration Commission (SASAC) held a meeting to promote value creation actions among state-owned enterprises, emphasizing the importance of strategic safety, industry leadership, and comprehensive support [2][3][9] - The approval of the Yangtze River Delta Spatial Planning (2023-2035) marks a new phase in regional integration, focusing on urban agglomeration and enhancing Shanghai's leading role [3][9] Market Performance - As of December 4, the Shanghai Composite Index closed at 3,875.79 points, down 0.06%, while the Shenzhen Component Index rose by 0.40% to 13,006.72 points, and the ChiNext Index increased by 1.01% to 3,067.48 points [4][10] - The market saw 1,446 stocks rise and 3,667 stocks fall, indicating a challenging environment for many equities [10] Capital Flow - The market turnover was reported at 15,617.68 billion yuan, showing a decline compared to the previous trading day [5][11] - The margin trading balance was recorded at 24,825.92 billion yuan, also down from the previous day [11]

证券之星消息，12月4日，深港通医疗（983035）指数报收于4472.99点，跌0.53%，成交59.38亿元，换 手率0.69%。当日该指数成份股中，上涨的有18家，微创机器人-B以5.48%的涨幅领涨，下跌的有38家， 一脉阳光以7.29%的跌幅领跌。 深港通医疗（983035）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 14.56% | 200.00 | 0.25% | | 2424.88 | 一 医药生物 | | sz300015 | 爰尔眼科 | 11.62% | 11.23 | -1.06% | | 1047.24 | 医药生物 | | sz300003 | 乐普医疗 | 4.85% | 15.66 | -0.89% | | 288.68 | 医药生物 | | sz300896 | 爱美客 | 4.80% | 140.41 | -2.29% | S | 424.87 | 美 ...

资金流向方面，深港通医疗(港币)（983036）指数成份股当日主力资金净流出合计3.3亿元，游资资金净 流入合计979.64万元，散户资金净流入合计3.2亿元。成份股资金流向详情见下表： 证券之星消息，12月4日，深港通医疗(港币)（983036）指数报收于4382.53点，跌0.57%，成交65.4亿 元，换手率0.69%。当日该指数成份股中，上涨的有18家，微创机器人-B以5.48%的涨幅领涨，下跌的有 38家，一脉阳光以7.29%的跌幅领跌。 深港通医疗(港币)（983036）指数十大成份股详情如下： | 深港通医疗(港币)指数 十大成份股 | | --- | | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 14.56% | 200.00 | 0.25% | 2424.88 | 医药生物 | | sz300015 | 爰尔眼科 | 11.62% | 11.23 | -1.06% | 1047.24 | 医药生物 | | sz3 ...

分析师：张刚 登记编码：S0730511010001 zhanggang@ccnew.com 021-50586990 航天机器人领涨 A 股小幅整理 ——市场分析 相关报告 《市场分析：煤炭有色行业领涨 A 股震荡整 固》 2025-12-03 《市场分析：船舶医药行业领涨 A 股震荡整 固》 2025-12-02 《市场分析：通信半导体领涨 A 股震荡上行》 2025-12-01 联系人： 李智 电话： 0371-65585629 地址： 郑州郑东新区商务外环路10号18楼 地址： 上海浦东新区世纪大道 1788 号 T1 座 22 楼 证券研究报告-市场分析 发布日期：2025 年 12 月 04 日 投资要点： ◼ A 股市场综述 周四（12 月 04 日）A 股市场冲高遇阻、小幅震荡整理，早盘股指高 开后震荡上行，盘中沪指在 3885 点附近遭遇阻力，随后股指震荡回 落，盘中机器人、航天航空、半导体以及汽车零部件等行业表现较 好；船舶制造、旅游酒店、食品饮料以及美容护理等行业表现较 弱，沪指全天基本呈现小幅整理的运行特征。创业板市场周四震荡 上扬，创业板成分指数全天表现强于主板市场。 ◼ 后市研判及 ...

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4495.04 points, down 0.66%, with a trading volume of 6.607 billion yuan and a turnover rate of 0.76% [1] - Among the index constituents, 11 stocks rose while 46 fell, with Xianjian Technology leading the gainers at 5.38% and Health Road leading the decliners at 5.3% [1] Index Constituents - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (14.56% weight) at 199.50 yuan, down 0.56% [1] - Aier Eye Hospital (11.62% weight) at 11.35 yuan, down 1.30% [1] - Lejin Medical (4.85% weight) at 15.80 yuan, up 0.38% [1] - Aimeike (4.80% weight) at 143.70 yuan, down 0.94% [1] - Yuyue Medical (4.66% weight) at 36.03 yuan, up 0.59% [1] - Yingke Medical (3.64% weight) at 43.22 yuan, up 1.93% [1] - Furuishi (3.59% weight) at 66.98 yuan, down 0.56% [1] - Meinian Health (3.58% weight) at 5.13 yuan, down 1.54% [1] - Sinopharm (3.35% weight) at 18.52 yuan, down 0.59% [1] - Ping An Good Doctor (2.63% weight) at 13.20 yuan, down 1.43% [1] Capital Flow - The index constituents experienced a net outflow of 301 million yuan from institutional investors, while retail investors saw a net inflow of 174 million yuan [3] - Notable capital flows include: - Meihua Medical with a net inflow of 21.18 million yuan from institutional investors [3] - Kefu Medical with a net inflow of 14.75 million yuan from institutional investors [3] - Yuyue Medical with a net inflow of 6.16 million yuan from institutional investors [3] Recent Adjustments - The Shenzhen-Hong Kong Medical Index has undergone adjustments, with one new stock added in the last ten days [3]

证券之星消息，12月3日，深港通医疗(港币)（983036）指数报收于4406.01点，跌0.65%，成交72.8亿 元，换手率0.76%。当日该指数成份股中，上涨的有11家，先健科技以5.38%的涨幅领涨，下跌的有46 家，健康之路以5.3%的跌幅领跌。 深港通医疗(港币)（983036）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 14.56% | 199.50 | -0.56% | 2418.82 | 医药生物 | | sz300015 | 爰尔眼科 | 11.62% | 11.35 | -1.30% | 1058.43 | 医药生物 | | sz300003 | 乐晋医疗 | 4.85% | 15.80 | 0.38% | 291.26 | 医药生物 | | sz300896 | 爱美客 | 4.80% | 143.70 | -0.94% | 434.82 | 美容护理 | | sz002223 ...

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (HKD) closed at 4433.77 points, down 0.69%, with a trading volume of 6.716 billion HKD and a turnover rate of 0.73% [1] - Among the index constituents, 18 stocks rose while 39 stocks fell, with Global Medical leading the gainers at 3.66% and Health Road leading the decliners at 6.35% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (14.56% weight, latest price 200.62, market cap 243.24 billion) [1] - Yier Eye Hospital (11.62% weight, latest price 11.50, market cap 107.24 billion) [1] - Lejin Medical (4.85% weight, latest price 15.74, market cap 29.01 billion) [1] - Aimeike (4.80% weight, latest price 145.06, market cap 43.89 billion) [1] - Yuyue Medical (4.66% weight, latest price 35.82, market cap 35.91 billion) [1] - Yingke Medical (3.64% weight, latest price 42.40, market cap 27.78 billion) [1] - Furuide (3.59% weight, latest price 67.36, market cap 17.85 billion) [1] - Meinian Health (3.58% weight, latest price 5.21, market cap 20.39 billion) [1] - Sinopharm (3.35% weight, latest price 18.63, market cap 58.14 billion) [1] - Ping An Good Doctor (2.63% weight, latest price 13.39, market cap 28.93 billion) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 83.77 million HKD, while retail investors saw a net inflow of 61.08 million HKD [1] - Specific stock capital flows include: - Mindray Medical: main fund net inflow of 37.11 million, retail net outflow of 4.23 million [2] - Yuyue Medical: main fund net inflow of 3.70 million, retail net inflow of 4.71 million [2] - Over the past 10 days, one stock was newly added to the index [2]

Core Viewpoint - The Shenzhen-Hong Kong Medical Index (983035) closed at 4523.97 points, down 0.72%, with a trading volume of 6.097 billion yuan and a turnover rate of 0.73% on December 2 [1]. Group 1: Index Performance - Among the index constituents, 18 stocks rose while 39 stocks fell, with Global Medical leading the gainers at a 3.66% increase and Health Road leading the decliners at a 6.35% decrease [1]. - The top ten constituents of the Shenzhen-Hong Kong Medical Index include major companies such as Mindray Medical (14.56% weight, latest price 200.62 yuan, -0.50% change) and Aier Eye Hospital (11.62% weight, latest price 11.50 yuan, -0.60% change) [1]. Group 2: Capital Flow - The net outflow of main funds from the index constituents totaled 83.77 million yuan, while retail investors saw a net inflow of 61.08 million yuan [3]. - Specific stock capital flows indicate that Mindray Medical experienced a net inflow of 37.11 million yuan from main funds, while it faced a net outflow of 32.88 million yuan from speculative funds [3]. - The index constituents underwent an adjustment in the last 10 days, with one new stock added [3].

Investment Rating - The industry maintains a "Recommended" rating, focusing on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][27]. Core Insights - The report highlights a significant increase in retail performance, with major sectors like retail, social services, and beauty care showing positive growth rates of +3.45%, +3.92%, and +0.50% respectively during the week of November 24-28, 2025 [14][22]. - The implementation plan by six departments aims to enhance the adaptability of supply and demand in consumer goods, targeting the formation of three trillion-level consumption fields and ten hundred-billion-level consumption hotspots by 2027 [3][22]. - Key companies such as Chow Tai Fook and Luk Fook have reported impressive same-store sales growth, with Chow Tai Fook's same-store sales in mainland China increasing by 38.8% from October 1 to November 18, 2025 [4][22]. Summary by Sections Market Performance - The report indicates that the retail, social services, and beauty care sectors ranked 9th, 6th, and 26th among 31 primary industries, with the Shanghai Composite Index rising by 1.40% and the Shenzhen Component Index by 3.56% during the same period [14][18]. Key Industry Events and Information - The report discusses various industry developments, including the registration of a new medical device by Jinbo Bio in the Philippines and the performance of travel company Tongcheng Travel, which reported a revenue of 5.509 billion yuan in Q3 2025, up 10.4% year-on-year [3][22]. - The release of "Zootopia 2" on November 26, 2025, achieved a record box office of 228 million yuan on its first day, indicating strong demand for related merchandise [3][22]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Ltd., Juzhi Bio, Marubi Biotechnology, Runben Co., Ltd., Proya, Chao Hong Ji, and Furuida, which are positioned well within the beauty care and new consumption sectors [5][27].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% from the current price [5][10]. Core Insights - The company plans to repurchase up to approximately 104 million shares, which is about 9.7% of its total shares, signaling management's confidence in the company's future and belief that the stock is undervalued [6][7]. - The company has received its first Class III medical device certification for its recombinant type I α1 collagen product, marking its entry into the injectable aesthetic medicine market, which is expected to drive future growth [7]. - Despite recent stock price adjustments due to market conditions and lower-than-expected sales during the Double Eleven shopping festival, the report suggests that the stock has sufficiently adjusted and is poised for recovery [7]. Financial Projections - The company is projected to achieve net profits of RMB 2.43 billion, RMB 2.98 billion, and RMB 3.64 billion for the years 2025, 2026, and 2027, respectively, reflecting year-over-year growth rates of 17.8%, 22.5%, and 22.2% [9]. - Earnings per share (EPS) are expected to be RMB 2.27, RMB 2.78, and RMB 3.40 for the same years, with corresponding year-over-year growth rates of 8.1%, 22.5%, and 22.2% [9]. - The price-to-earnings (P/E) ratios are projected to decrease from 15x in 2025 to 10x in 2027, indicating a potential increase in value as the company grows [9]. Shareholder Information - The major shareholder is Fan Daidi, holding 55.13% of the shares, which indicates a strong control over the company [1]. - The company's market capitalization is approximately HKD 41.08 billion, with a current share price of HKD 36.58 [1]. Market Performance - The stock has experienced a significant decline, with a 24.4% drop over the past month and a 32.07% drop over the past three months [1]. - The stock price has fluctuated between a high of HKD 82.99 and a low of HKD 35.72 over the past year [1]. Product Portfolio - The company's product mix is heavily weighted towards functional skincare products, which account for 78.6% of total sales, while medical dressings contribute 23.3% and health products account for 0.3% [2].